OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going ... the receptors for an appetite- and blood sugar-reducing hormone called GLP-1. But the company was "looking at ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Despite normal hormone levels in her blood tests ... 4 No formal studies have established a link between breast parenchymal growth and the Pfizer COVID-19 vaccine. Although these social media ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...